Celularity (NASDAQ:CELU) is a biotechnology company focused on developing cellular therapies for cancer, infectious diseases, and degenerative diseases. The company harnesses the power of cells, particularly placental-derived cells, to create innovative medical treatments. Celularity is at the forefront of research and development in regenerative medicine, aiming to unlock new therapeutic pathways and improve outcomes for patients facing serious health conditions. Their projects span across various phases of clinical trials, demonstrating their commitment to advancing healthcare through cutting-edge science. Celularity's objectives include accelerating the availability of transformative treatments that can significantly enhance patient care and quality of life, while also exploring the vast potential of cellular medicine to address unmet medical needs.